Atrial fibrillation ablation with advanced radiofrequency catheter versus second-generation cryoballoon catheter

Tweetable abstract Lower hospital cost and readmission burden was observed among atrial fibrillation patients undergoing ablation using the THERMOCOOL SMARTTOUCH (TM) SF catheter versus the Arctic Front Advance (TM) catheter. Aim: To compare cost and readmissions among atrial fibrillation (AF) patients undergoing ablation using the THERMOCOOL SMARTTOUCH (TM) SF (STSF) radiofrequency catheter versus the Arctic Front Advance (TM) (AFA) cryoballoon catheter. Patients & methods: The Premier Healthcare Database was used for the study purposes. Propensity score matching was used to match patients in the two groups. Costs and readmissions were assessed. A regression model was used for outcome assessment. Results: After propensity matching, 2767 patients were identified in each of the STSF and AFA cohorts. In the matched cohort, STSF patients had significantly lower supply costs than AFA patients. STSF patients had significantly lower 4-12-month AF-related inpatient readmissions compared with AFA patients (2.58% vs 3.99%; p = 0.0402). Costs of care summing index procedure and readmission costs were also lower for the STSF patients versus AFA patients. Conclusions: Patients who underwent AF ablation using the STSF catheter versus the AFA catheter had lower cost and AF-related readmissions.